Dear Mr. Clavelli:

Please refer to your supplemental new drug applications dated August 19, 2003 (capsules) and August 26, 2003 (injection), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Geodon (ziprasidone HCl) Capsules and Geodon (ziprasidone mesylate) for Injection.

These “Changes Being Effected” supplemental new drug applications provide a clarification in the second paragraph of the Intramuscular Administration - Preparation for Administration subsection of the Dosage and Administration section of labeling as follows (added sentence underlined):

"Add 1.2 mL of Sterile Water for Injection to the vial and shake vigorously until all the drug is dissolved. Each mL of reconstituted solution contains 20 mg ziprasidone. To administer a 10 mg dose, draw up 0.5 mL of the reconstituted solution. To administer a 20 mg dose, draw up 1.0 mL of the reconstituted solution. Since no preservative or bacteriostatic agent is present in this product, aseptic technique must be used in preparation of the final solution. This medicinal product must not be mixed with other medicinal products or solvents other than Sterile Water for Injection."

We have completed our review of these applications, as amended. These applications are approved, effective on the date of this letter, for use as recommended in the submitted labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 20-825 / SLR-008 and supplement NDA 20-919 / SLR-001." Approval of these submissions by FDA is not required before the labeling is used.
If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD  20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Steven D. Hardeman, R.Ph., Senior Regulatory Project Manager, at (301) 594-5525.

Sincerely,

[See appended electronic signature page]

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Russell Katz
12/23/03 08:56:04 AM